Esophageal and Gastroesophageal Junction Carcinoma

Esophageal and Gastroesophageal Junction Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 460
Recruiting: 254
Ph III recruiting: 40
Growth YoY: +36.1%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (120)

clinicaltrialsPublishedShowing 51–100 of 550 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07714538	Breath Research Narrow Validation for Gastrointestinal Cancer Detection(BRAVE)	recruiting	—	1,000	Imperial College LondonOTHER	1	Sep 11, 2026	clinicaltrials
NCT01142388	Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer	active not recruiting	Phase 2	94	National Cancer Institute (NCI)NIH	1	Sep 10, 2026